Z79.69Long term (current) use of other immunomodulators and immunosuppressants

Z79.69 is the ICD-10-CM diagnosis code for long term (current) use of other immunomodulators and immunosuppressants. It belongs to category Z79 (long term (current) drug therapy), block Z77-Z99 (persons with potential health hazards related to family and personal history and certain conditions influencing health status) and chapter 21 (factors influencing health status and contact with health services). It is billable, so it can be reported on its own for dates of service from October 1, 2026 through September 30, 2027.

Within Z79.6, choose Z79.69 (other immunomodulators and immunosuppressants) only when documentation doesn't support a more specific option: unspecified immunomodulators and immunosuppressants (Z79.60), immunomodulator (Z79.61), immunosuppressant (Z79.62), chemotherapeutic agent (Z79.63) and myelosuppressive agent (Z79.64).

It is not a CC or MCC, so as a secondary diagnosis it doesn't change the MS-DRG severity level.

In MS-DRG v44.0, it is part of the grouping logic for DRG 949 (Aftercare with CC/MCC, relative weight 1.123) and DRG 950 (Aftercare without CC/MCC, relative weight 0.7664), in MDC 23 (Factors Influencing Health Status and Other Contacts with Health Services), as a principal or secondary diagnosis. The DRG a claim lands in depends on the principal diagnosis, procedures and any CC/MCC secondary diagnoses.

It is not acceptable as the principal diagnosis for an inpatient stay; it may be reported as a secondary diagnosis.

It is exempt from present-on-admission (POA) reporting, so no POA indicator is required.

It was added in FY2023, effective October 1, 2022.